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5Executive Summary
The West Virginia economy, along with many other states, has undergone significant changes 
in its overall economic structure. Manufacturing employment continues to decline while  
service related jobs continue to grow. As part of the process of identifying new opportunities to 
grow the state economy, policy makers and economists have identified industry clusters that 
have potential for advancing the state’s economy. In recent years the bioscience industry has 
received increasing attention and study. For the purposes of this report this industry has four 
major subsectors: agricultural feedstock and chemicals, drugs and pharmaceuticals, medical 
devices and equipment, and research, testing and medical laboratories.
National studies by the Battelle Memorial Institute and the Milken Institute have identified the
bioscience industry as an attractive target for states seeking to stimulate economic growth. 
This industry has strong job growth and wages well above the national private sector level. As 
a result, states have been fashioning their public policies to support the continued growth of 
this industry cluster.
This study estimates the economic impact (direct, indirect and induced, and total) of the West
Virginia bioscience industry in 2006. The following table summarizes these impacts: 
The report presents a detailed profile of the West Virginia bioscience industry over the period
2001-2006. Major findings include:
 •  Within the bioscience industry, the agricultural feedstock and chemical sub-sector 
as well as the drugs and pharmaceutical sub-sector have a greater concentration 
in West Virginia than the nation as a whole. The Charleston MSA has a relatively 
high concentration of agriculture feedstock and chemicals employment while the 
Morgantown MSA has a very high concentration of employment in the drugs and 
pharmaceutical sub-sector.
 •  West Virginia bioscience employment ranged from 6,928 in 2001 to 6,912 in 2006.
Significant employment declines of 1,151 jobs in the All Other Basic Organic 
Chemical Manufacturing Sector were largely offset by employment gains in the 
6other bioscience sectors.
 •  West Virginia bioscience average earnings in 2006 were $55,220 compared to 
statewide average earnings of $37,894.
 •  Bioscience employment was largely concentrated in the Charleston, Huntington 
and Morgantown Metropolitan Statistical Areas as well as Tyler County.
National studies on the bioscience industry acknowledge the importance of research  
undertaken in higher education; however, most studies do not estimate the economic impact 
of this research. University based research is a very important component for the  
development of human capital as well as the commercialization of research in the private 
sector. The following table summarizes the economic impact of the life sciences research 
undertaken at West Virginia University, Marshall University and the West Virginia School of 
Osteopathic Medicine during FY2007. 
The study also reviews a variety of state level public policy measures critical to the growth 
and development of the industry. West Virginia has numerous efforts underway, as well as 
new initiatives that will create an environment more attractive and welcoming to the  
bioscience sector.
West Virginia is well positioned to grow its bioscience industry through investments in
additional higher education research support along with support of current and new state and
regional initiatives fostering additional investment and job creation in this industry.
7Introduction and Overview
The West Virginia economy, along with many other states, has undergone significant changes 
in its overall structure. Following the national trend, manufacturing employment continues to
decline while service related jobs continue to grow. While there has been a recent upturn in 
West Virginia energy employment due to rising coal and natural gas prices, there has been a 
long term decline in energy employment. The loss of high wage employment and relatively low 
levels of educational attainment statewide have led to a per capita income of $28,067 in 2006, 
which was 77 percent of the national average of $36,629.2
In the last twenty years, West Virginia policy makers and economists have identified industry
clusters that had the potential for advancing the state’s economy. The Bureau of Business and
Economic Research at West Virginia University has issued comprehensive reports on two 
such clusters—chemicals and polymers, along with recommendations for public policies to  
support the growth of these sectors.3
In the last several years the bioscience industry has received increasing attention in the 
United States. This industry has four major subsectors: agriculture feedstock and chemicals, 
drugs and pharmaceuticals, medical devices and equipment, and research, testing, and  
medical laboratories. All these sectors have shown considerable growth nationally.
This report reviews national studies on the bioscience industry and their implications for West
Virginia. The report also includes a comprehensive profile of the bioscience industry in West
Virginia as a whole and by county. Major economic indicators such as employment, earnings,
and number of establishment are reviewed. Based upon the economic information in 2006 the
economic impact of the industry is estimated and put in context with other major sectors.4 The
report concludes with a review of state policies promoting the growth of this industry and
updates West Virginia’s efforts.
National Studies on the Bioscience Industry and Their Implications for
West Virginia
Over the past several years both the Battelle Memorial Institute and the Milken Institute have
released major studies on the bioscience industry.5 With a promising future ahead, the  
bioscience sector is an attractive target for states seeking to stimulate economic growth. The 
sector encompasses a group of industries and activities, linked by the application of  
knowledge of the way in which plants, animals, and humans function, that stem from the  
convergence of the biological sciences, engineering, and information technology. Due to 
strong job growth and wages which are typically well above the national private sector  
2 Source: Bureau of Economic Analysis, U.S. Department of Commerce, BEARFACTS, http://bea.gov/regional/bearfacts.
3  See David Greenstreet, Overview of Economic Aspects of the Polymer Alliance Zone, BBER, 1996 and David Greenstreet, Economic Prospects 
of the Central West Virginia Chemical Industry with Recommendations Regarding a Potential Chemical Alliance Zone, BBER, 1998.
4 Definitions of various types of economic impacts examined in this report can be found in Appendix A Table 7.
5  Battelle Technology Partnership Practice and SSTI, Growing the Nation’s Bioscience Sector: State Bioscience Initiatives 2006, prepared for 
the Biotechnology Industry Organization, April 2006, available at www.bio.org. Milken Institute, Biopharmaceutical Industry  
Contributions to State and U.S. Economies, October 2004, available at www.milkeninstitute.org.
8average, the competition among states and regions to attract bioscience firms is intense. 
State-based initiatives are wide-ranging in their focus and funding levels, and will be covered 
below.
Within biosciences, the Battelle report identified four subsectors: agriculture feedstock and
chemicals, drugs and pharmaceuticals, medical devices and equipment, and research,  
testing, and medical laboratories. A detailed listing of these sectors is provided in Table 1.  
As a note, academic institutions with major life sciences research (includes bioscience) were 
not included in the Battelle Memorial Institute study due to data restraints.
The Battelle report indicates that in 2004 total employment in the bioscience sector reached 
1.2 million nationally, with medical devices and equipment, and research, testing, and  
medical laboratories each accounting for 33 percent of the total, and drugs and  
pharmaceuticals holding a 25 percent share.6 Bioscience sector employment increased by 
just over 1 percent between 2001 and 2004, whereas overall U.S. employment decreased 
by 0.7 percent. Within biosciences, research, testing, and medical laboratories registered the 
fastest employment growth, at 8 percent between 2001 and 2004, with drugs and  
pharmaceuticals registering 3 percent growth. Agricultural feedstock and chemicals, and 
medical devices and equipment each showed declines during the period. Overall, the  
bioscience sector accounted for about 1.1 percent of U.S. employment during 2004.
As could be expected, the 1.2 million jobs attributed to the bioscience sector nationally have 
both directly and indirectly spurred other job opportunities.7 Using RIMS II economic  
multipliers8, a methodology permitting the tracing of the interrelationships between  
expenditures in the bioscience sector and other parts of the economy, the Battelle Memorial 
Institute attributed an additional 5.8 million jobs to suppliers and other firms, for a total impact 
of 7.0 million jobs. Along with this job creation, another primary attraction of the bioscience 
sector involves the relatively high wages paid to workers in the industry. The average annual 
wage of bioscience workers in the U.S. was $65,775 in 2004, nearly $26,000 higher than the 
average private sector annual wage in the U.S. Furthermore, real earnings increased by 6.4 
percent between 2001 and 2004, compared to a 1.4 percent increase for the average private 
sector worker.
The four sub-sectors of biosciences encompass a wide range of activities, offering states an
opportunity to capitalize on sector growth in several different areas. Agricultural feedstock 
and chemicals includes the production and processing of organic and agricultural chemicals 
and feedstock. Companies such as Archer Daniels Midland, Bayer CropScience, Cargill, 
Dow, DuPont, Monsanto, and others in this sector focus on the production of biodiesel fuels, 
plantbased biodegradable materials, fertilizers and pesticides, sustainable oils and lubricants,
biocatalysts, and food and feed additives and ingredients. 
6  The Battelle report used data provided by the Minnesota Implan Group, Inc. (www.implan.com). The data on employment, earnings 
and established by industry is based upon the North American Industrial Classification System (NAICS), which is the standard  
established by the federal government for the classification of industries.
7 Appendix A Table 7 provides a definition of the economic impact concepts covered in this report.
8  The RIMS II economic multipliers were prepared by the Bureau of Economic Analysis, U.S. Department of Commerce. For further 
information see http://www.bea.gov/bea/regional/rims.
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In order to assess whether the agricultural feedstock and chemicals sub-sector is  
concentrated in West Virginia, or if it is relatively under-represented compared to the nation 
as a whole, a location quotient is used. The location quotient is derived by dividing the share 
of employment of a particular industry in a location by the share of employment of the same 
industry in a comparison region such as the nation. If the location quotient is above 1, the 
industry is relatively concentrated in that location; if it is less than 1, there might be  
opportunities for industry expansion. For West Virginia, the agricultural feedstock and  
chemicals sub-sector has a location quotient of 1.2, indicating a 20 percent greater  
concentration of agricultural feedstock and chemicals employment than the national average. 
Moreover, at a more specific geographic level, the Charleston Metropolitan Statistical Area 
(MSA) is noted as having a relatively high concentration of agriculture feedstock and  
chemicals employment than is found nationally.
The drugs and pharmaceuticals sub-sector was one of two bioscience sub-sectors that  
registered positive employment growth nationally between 2001 and 2004. Composed of 
therapeutic and diagnostic substances, sub-sector activities include the production of  
vaccines, oncology, neurology and cardiology treatments, herbal supplements and vitamins, 
tissues and cell culture media, and dermatological and topical treatments. Leading  
companies include Abbot, Amgen, Biogen, Genentech, MedImmune, Merck, Novartis, Pfizer, 
Roche, and Sanofi-Aventis. Here again, West Virginia has a larger share of its employment 
in this sub-sector than the nation, with a location quotient between 1.00 and 1.20. Also, the 
Morgantown MSA stands well above many similar sized MSAs, with a location quotient of 
15.26 and 1,553 drugs and pharmaceuticals employees in 2004.
The medical devices and equipment sub-sector accounted for close to one-third of total
bioscience sector employment in 2004. Focused on medical supplies, devices, and  
equipment, this sub-sector encompasses bio-imaging equipment, orthopedic and prosthetic 
implants and devices, dental instruments and orthodontics, laser eye surgery instruments, 
automated external defibrillators, vascular stents and other implantable devices. Bausch & 
Lomb, Boston Scientific, Ethicon, GE Healthcare, Medtronic, Siemens Medical Solutions, 
Stryker, and 3M Health Care are the major players within medical devices and equipment. 
The sub-sector is not well represented in West Virginia, however, with a location quotient  
below 0.80. The Parkersburg-Marietta MSA does have a location quotient of 2.06 and  
employment of 448, indicating a concentration in this metro area above the national level.
Research, testing, and medical laboratories not only accounted for another one-third of total
bioscience sector employment, but it also registered strong job gains between 2001 and 
2004. Activities in this sub-sector include functional genomics and drug discovery techniques,
diagnostic testing, preclinical drug therapeutics, protein receptors, drug delivery technology,
research models and laboratory support services. Sub-sector leaders include Cellomics, 
Charles River Labs, Diversa, Invitrogen, Laboratory Corp. of America, Pharmacopeia Drug 
Discovery, Quest Diagnostics, and ViaCell. West Virginia is under-represented in this  
sub-sector, with a location quotient below 0.80.
Similar to the bioscience sector described above, the biopharmaceutical industry holds the
promise of growing companies and an increasing number of well-paying jobs, according to 
the
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Milken Institute Study in 2004. The biopharmaceutical industry is an outgrowth of  
interdisciplinary research in molecular biology, immunology, and biochemistry and should be
viewed as part of the bioscience sector. Recent biopharmaceutical growth stems from many
traditional pharmaceutical firms seeking to supplement their product pipelines through  
external acquisitions or development of internal biotechnology divisions. In order to attract the 
attention of these firms and the industry itself, states are competing to offer a favorable and 
attractive environment. Moreover, the Milken Institute study pegged West Virginia as a state 
that has the potential to capitalize on the expanding biopharmaceutical industry.
The Milken Institute study indicated that in 2003 the biopharmaceutical industry directly
employed 406,700 people in the U.S and was responsible for a total of 2.7 million jobs  
including the indirect and induced impacts.9 Average annual wage for biopharmaceutical  
employees was $72,600, and the industry accounted for $63.9 billion in real output directly 
and $172.7 billion indirectly. The Milken Institute provides a 10-year projection for the 
industry, forecasting an increase in direct employment from 413,800 in 2004 to 536,300 in 
2014. Moreover, total employment attributed to the biopharmaceutical industry is expected 
to grow to 3.6 million jobs over the same time period. Along with several other states, West 
Virginia is expected to exhibit job growth above the national average between 2004 and 2014.
Biopharmaceutical companies are characterized by their high levels of research and
development, typically at least 20 percent of their overall sales, making them the most  
research-intensive sectors in the U.S. economy. Moreover, firms in this industry demand a 
skilled, welleducated labor force, access to research and risk capital funding, and an  
environment which encourages innovation. In order to be competitive in attracting  
biopharmaceutical companies, it is imperative that states enhance their research, financial 
and human capital infrastructures.
Hubs of biopharmaceutical activity are located in New England, the New Jersey-New York-
Pennsylvania region, and in several Midwest states. While the clustering of firms is apparent 
in some areas, the overall growth of the industry has lead many states to register favorable
biopharmaceutical growth in recent years. In the South Atlantic region, as defined by the 
Milken Institute and which includes West Virginia, North Carolina and Maryland dominate in 
terms of industry employment and output, while Delaware and the District of Columbia are 
also noted for their activity. As a whole, the region has outperformed the rest of the nation 
in terms of biopharmaceutical employment growth between 1983 and 2003. Perhaps most 
interesting, West Virginia led the region in terms of both employment growth (106.1 percent) 
and real output growth (214.2 percent) between 1993 and 2003. Real output per employee 
in West Virginia ($169,400) was third highest among the nine states in the region and wages 
per employee were the fifth highest ($56,800).
On a national scale, West Virginia’s 106.1 percent employment growth rate in the
biopharmaceutical industry between 1993 and 2003 ranks as the seventh-highest in the  
nation, while the real output growth rate during the same period (214.2 percent) is the  
fifth-highest in the U.S. The majority of West Virginia’s biopharmaceutical employment is 
9  The Milken Institute study also used the RIMS II multipliers for the NAICS sectors examined.
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concentrated in pharmaceutical and medicine manufacturing activity, relative to research and 
development (R&D) employment in the life sciences. 
The Milkin Institute report provides detailed biopharmaceutical data along with economic and
tax impacts for every state in the country. In 2003 West Virginia’s biopharmaceutical industry
directly employed 1,879 people and provided $106.8 million in earnings. Including multiplier
effects, the total number of jobs generated by the industry swells to 5,833 with $219.2 million 
in total earnings. The industry registered a total real output (measured in 1996 dollars) of 
$521.7 million in 2003, with 61 percent ($318.3 million) directly attributable to  
biopharmaceutical firms and $203.4 million in indirect and induced impacts. The industry had 
a total federal and state tax liability of $87 million, of which $69.9 million was due to personal 
income tax revenues, $2.2 million attributed to total sales tax revenues, and $15.1 million in 
corporate income tax revenues. The majority of economic activity generated by the  
biopharmaceutical industry in West Virginia stems from manufacturing (71.4 percent), while 
professional & scientific services is a distant second at 6.4 percent. The state and local tax 
liability were estimated at $19.5 million.
The Milken Institute study includes an index that evaluates states’ abilities to capitalize on
opportunities in the biopharmaceutical industry. The index is based upon the presence of a
suitable workforce, access to funding resources, and incentives for research activity. It also
encompasses a state and/or region’s research, financial, and human capital infrastructure. In
order to construct the index, four key requirements are judged: biopharmaceutical research
funding, biopharmaceutical risk capital funding, biopharmaceutical human capital and
workforce, and biopharmaceutical innovation output. Rather than comparing absolute  
measures of the four requirement areas, the data is scaled in order to evaluate the relative 
strengths of a state.
Research funding is a vital component in the development and potential commercialization
prospects of promising biopharmaceutical initiatives. Moreover, according to the Milken
Institute study, the level of research funding can be used as an indicator of a region’s future
innovative capacity, as it aids in attracting companies, the appropriate workforce, and  
necessary capital. Major national funding sources include the National Institutes of Health 
(NIH), National Science Foundation (NSF), and Small Business Administration (SBA), among 
others. As a component of the larger, overall biopharmaceutical index, the research funding 
index considers the following: biopharmaceutical investment in R&D, total NIH funding; NIH 
funding to biopharmaceutical industry; academic funding of biopharmaceutical R&D; NSF 
funding to the industry; Small Business Innovation Research funding; and Small Business 
Technology Transfer funding. In the Milken study, Massachusetts was ranked as the top state 
in the biopharmaceutical research funding index, with Connecticut and Maryland completing 
the top three positions. West Virginia was ranked 48th, above only South Dakota and Alaska, 
which occupied the 49th and 50th positions, respectively.
In order to enhance the commercialization potential of research discoveries, companies need
access to financial capital that will support these ventures. Risk capital, or venture capital,
funding is an important aspect of the biopharmaceutical industry and its small businesses 
and entrepreneurs. In order to evaluate this component of a state’s overall biopharmaceutical
development prospects, the Milken Institute study looks at three important aspects of risk 
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capital funding: biotech venture capital growth between 2001 and 2003, growth of biotech 
companies receiving venture capital, and biotech venture capital dollars per $100,000 of 
gross state product. 
Massachusetts was again the top ranked state, while West Virginia was tied for last with
seventeen other states which showed little or no biotech venture capital activity.
As with many industries, an educated workforce is vital for any development prospects. The
biopharmaceutical industry, in particular, requires an accessible supply of labor well-versed in
technology and science. The Milken Institute study measured states’ relative human  
capital by focusing on biopharmaceutical-related bachelor degree attainment levels as a 
share of total bachelor degree attainment, the percentage of people with advanced degrees, 
the percentage of graduate students enrolled in biological and medical sciences, and  
biological technician employment as a share of a state’s overall employment, among other 
measures. West Virginia ranked 22nd in this index component, with Delaware ranked first and 
South Dakota last.
The final component of the Milken Institute’s biopharmaceutical innovation pipeline index
relates to a state’s capacity for biopharmaceutical innovation, encompassing many different
indicators. The number of clinical (early, mid, and late-stage) trials measures
commercialization potential, while the number of new drug applications, count of  
biotechnology and pharmaceutical patents and patent citations, patent technology cycle time, 
and the share of biopharmaceutical patents as a percentage of total number of state patents, 
all evaluate the level and success of research discoveries. Also included in this component is 
the number of biotechnology companies on the ‘Technology Fast 500’ list, composed by  
Deloitte, which are located in the state. Massachusetts took the first spot in this index  
component, with Alaska ranked 50th. West Virginia was ranked 31st.
Using these four components (research funding, financial capital, educated workforce and
innovation pipeline), the Milken Institute study reports an overall state biopharmaceutical 
index. Not surprisingly, Massachusetts comes in as the top-ranked state, with Maryland and
Connecticut next in line. West Virginia is ranked 41st, one spot lower than Louisiana, but just
above Arkansas. Bottom-ranked states include Alaska, South Dakota, and Wyoming. The 
Milken Institute study notes that for states such as West Virginia, greater efforts at  
attracting research-intensive business, specially trained workers, and financial capital support 
are needed.
The Milken Institute study also provides projections from 2004-2014 for the industry at the
national and state levels. Direct biopharmaceutical employment in the United States is  
projected to grow from 413,800 in 2004 to 536,300 in 2014, while the total employment  
impact (sum of direct, indirect and induced) of the industry will generate over 3.6 million jobs 
by 2014. Real output contribution of the industry (1996 dollars) is expected to rise from $69.2 
billion in 2004 to $128.3 billion in 2014, while total (direct and indirect) real output is  
projected to increase to $350.1 billion. Finally, direct biopharmaceutical earnings are forecast 
to increase from $31.4 billion in 2004 to $56.6 billion in 2014, with the total earnings  
contribution rising to $218 billion.
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Industry employment according to the Milken Institute study is expected to grow in West
Virginia by 51.5 percent, as jobs increase from 1,960 in 2004 to 2,970 in 2014. Moreover, 
6,250 additional, indirect jobs are expected to be generated by the industry over the same 
time period. Biopharmaceutical real output (1996 dollars) is projected to increase to $1.1  
billion by 2014, then accounting for 2.1 percent of West Virginia’s total non-farm real output. 
This is an increase of 216.8 percent over 2004 levels, and is two-and-a-half times faster than 
the U.S. average.
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A Profile of the West Virginia Bioscience  
Industry10
Figure 1 illustrates employment in the bioscience sector for both West Virginia and the U.S.
between 2001 and 2006. In West Virginia, employment peaked at 7,070 in 2004, but has 
since declined somewhat to 6,912 in 2006, little changed from 2001. This decline is largely the 
result of significant employment declines in the All Other Basic Organic Chemical  
Manufacturing Sector (NAICS 325198) which had employment of 1,892 in 2001 and 741 in 
2006 (Table A-4). The U.S. has seen a steady increase in bioscience employment, from 1.59 
million in 2001 to 1.69 million in 2006.
As shown in Figure 2 (next page), bioscience employment in West Virginia in 2006 appears to 
be concentrated in four counties, each with at least 500 employees. Monongalia County leads 
the state with 2,269 workers, just above Kanawha County’s 2,033 workers. Cabell County 
showed 1,135 employees, while Tyler County registered 501. Sixteen counties witnessed no  
bioscience-related employment. West Virginia maps by county documenting the employment, 
earnings, and establishment data are presented in Appendix B.
In 2006, West Virginia saw activity in 15 of the 27 bioscience sub-sectors, with employment  
in those sub-sectors shown in Figure 3 (next page). Pharmaceutical preparation  
manufacturing employed the most workers, with 2,369. Physical, engineering, and  
biological research registered 1,142 employees, while testing laboratories showed 1,019 jobs 
during 2006. 
10  This section is based upon data provided by IMPLAN. Detailed data tables are available in Appendix A.
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In Figure 4 below, employment levels are shown for both the U.S. and West Virginia in
bioscience sub-sectors that were present in the state during 2006. The nation’s three largest 
sub sectors – physical, engineering, and biological research, pharmaceutical preparation
manufacturing, and testing laboratories – were also the state’s largest sub-sectors, in terms of
employment. 
Average annual growth rates of selected bioscience sub-sector employment between 2001 
and 2006 are illustrated in Figure 5 (next page) for both the U.S. and West Virginia.  
Laboratory apparatus and furniture manufacturing had the highest average annual growth 
rate in West Virginia, at 78.3 percent. On the other hand, the diagnostic imaging centers  
sub-sector witnessed the largest average annual growth rate in the U.S., at 6.1 percent.  
Two sub-sectors in West Virginia (Other Biological Product Manufacturing and Analytical  
Laboratory Instrument Manufacturing) saw their employment levels fall to zero during the 
period.
Figure 6 (next page) shows average annual growth rates of bioscience employment in West 
Virginia Counties between 2001 and 2006. Barbour County had the highest average annual 
growth rate at 110.2 percent, as employment increased from 1 to 41. The state’s average  
annual growth rate was very close to zero, while several counties saw employment levels fall 
to zero, represented by a growth rate of -100 percent. Counties not included did not have  
sufficient bioscience employment over the period to calculate an average annual growth rate. 
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The absolute change in bioscience employment by county, from 2001 to 2006, is shown in 
Figure 7 (previous page). Monongalia County gained 849 jobs during the period, the largest 
of any county in the state. In contrast, bioscience employment fell by 1,212 jobs in Kanawha 
County, the largest decline among counties. The latter was largely due to the job losses at 
Dow Chemicals when it downsized its South Charleston Division.
Average annual earnings in the bioscience sector are shown in Figure 8 (previous page) for 
West Virginia counties in 2006. Bioscience positions in Tyler County averaged $73,871 per 
year, nearly double the state average of $37,894.11 Five other counties – Berkeley, Kanawha, 
Marion, Monongalia, and Hancock – joined Tyler County in having average annual bioscience 
earnings above the state average.
In Figure 9 below, average annual earnings for each bioscience sector is shown for West 
Virginia during 2006. The highest average annual earnings were seen in the All Other Basic 
Organic Chemical Manufacturing sector, at $81,913, while Pharmaceutical Preparation
Manufacturing was the next highest at $68,136. Phosphatic Fertilizer Manufacturing had the
lowest average annual earnings, at just below $16,000. 
The average annual growth rate of earnings in the West Virginia bioscience sector between 
2001 and 2006 is shown in Figure 10 (next page). Earnings in the diagnostic imaging centers  
11  Bureau of Economic Analysis, U.S. Department of Commerce, State Economic Profiles-West Virginia, Table SA30.
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sub-sector experienced an average annual growth rate of 6.7 percent, the highest of any 
sub-sector. Surgical appliance and supplies manufacturing saw the second-fastest average 
annual growth rate in earnings, at 6.2 percent. Sub-sectors not shown in the figure did not 
have sufficient available earnings data in order to calculate an average annual growth rate.
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According to Figure 11 (previous page), Kanawha County has the highest number of  
bioscience establishments in 2006, with 44. Cabell County and Monongalia County contained 
25 and 21 establishments, respectively. Thirteen counties did not have any bioscience  
establishments during 2006. The total number of bioscience establishments in West Virginia 
was 241.
West Virginia bioscience establishments were concentrated in the testing laboratories  
sub-sector, with 72 throughout the state. Figure 12 below shows that physical, engineering, 
and biological research and medical laboratories are the next two largest sub-sectors, in 
terms of number of establishments, with 53 and 32, respectively. 
Figure 13 (next page) illustrates bioscience employment in West Virginia in 2006 by the four
supersectors, as defined by the Battelle Memorial Institute study. West Virginia registered the
largest bioscience employment in the research, testing, and medical laboratories supersector,
with drugs and pharmaceuticals the second largest. Medical devices and equipment and
agricultural feedstock and chemicals witnessed substantially fewer employees than the two
largest.
In Figure 14 (next page), earnings by supersector are shown for bioscience employment in 
West Virginia during 2006. Employees in the agricultural feedstock and chemicals  
supersector had the highest average annual earnings at $79,736, with drugs and  
pharmaceuticals next at $68,037. Research, testing, and medical laboratories had the third 
highest average annual earnings, at $42,439, while medical devices and equipment averaged 
$40,290.
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State Initiatives to Promote the  
Bioscience Industry
States are implementing various initiatives aimed at promoting the development of the  
bioscience industry. For the most part, these initiatives fall into one of the following categories:
building R&D capacity, encouraging academic/industrial interaction, providing  
commercialization assistance, enhancing access to capital, creating office space for emerging
companies, and supporting relevant workforce development and education programs. Not 
every state has a program in each category, nor are the initiatives being implemented within 
each category the same. A short overview of programs in each category is described below. 
Table 2 also provides a short summary of many of these programs.12
In their attempts to build R&D capacity, states are implementing faculty development and
bioscience research programs, along with investing in bioscience R&D infrastructure. In order 
to encourage greater collaboration between academic institutions and industry, matching grant
programs for universities and industry have been developed, along with facilities that serve 
both academic researchers and industry participants. Commercialization assistance is being
accomplished through technology transfer funding and entrepreneur support. Access to capital
has been enhanced by states through seed capital programs, tax credits, and grants, as well 
as creation of public and private venture capital funds. Companies’ need for space is being 
met by the development of bioscience incubators and research parks. Finally, states are  
supporting the bioscience industry’s requirement of a well-educated workforce by  
implementing talent recruitment programs, and by encouraging a greater K-12 focus on math 
and science and post-secondary education programs.
Creating an attractive overall environment for the bioscience industry is vital to state
competitiveness in the sector and is the motivation for building R&D capacity. Infrastructure
improvements are being accomplished through state grants, loans, and bond funding that
supports construction. Support for research programs is achieved by states primarily through
funding assistance. Competitive R&D awards, direct grant and matching funds programs, 
seed funding for start-up companies, and support of research centers directly are initiatives 
currently being used by states to encourage research. Finally, faculty development programs 
are being pursued by several states, primarily through the creation of endowments that will 
provide funding in order to attract prominent researchers and scholars. Along with bond  
funding, several other creative funding programs exist, such as Georgia’s ‘tax check-off’ 
donation program on personal income tax returns that directs funding to the Georgia Cancer 
Research Fund, Louisiana’s use of a portion of its cigarette tax, and several states’ use of 
tobacco settlement funds for bioscience funding.
The Battelle Memorial Institute study notes that as the number of corporate research  
laboratories has declined in recent years, academic institutions offer the bioscience industry 
important access to advanced R&D capabilities. States are employing matching grant  
programs for research partnerships. By supplementing the funds gained from federal, private, 
12  This section is largely based upon the results provided by the Battelle Memorial Institute study.
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or industry aid, state matching programs are helping to stimulate interaction between industry 
and education institutions. Furthermore, greater collaboration between industry and  
universities can be accomplished through shared facilities. Several states have contributed 
funding resources to construction of these facilities.
The benefits of research and innovation are realized through widespread adaptation of a new
ideas or processes. Therefore, the entrepreneurs in the research-intensive bioscience 
industry are likely to be attracted to states which assist in the commercialization of research 
discoveries. Some states have directed funding to assist with university-based technology 
transfer centers, while others are supporting free-standing centers to provide assistance to 
new companies. Also, states are developing commercialization funds to provide early-stage 
financing for companies; these funds range in size from $200,000 to $20 million. Finally,  
programs to assist entrepreneurs with business development are being put into place by 
many states. These programs offer support services that include business mentoring,  
planning support, advisory forums, and financial assistance, among others.
Financing is a very important component of state assistance to bioscience start-ups, as well 
as other entrepreneurs. Battelle notes that while private financing firms have grown in size, 
this has reduced, somewhat, their contributions to start-ups very early in their lives.  
Therefore, states have stepped in to provide and/or encourage seed capital funding.  
Numerous states offer tax credits targeting investors in technology and bioscience firms. Two 
states have bioscience-specific tax credits, while seven others have bioscience seed funds. 
Also, several states are also providing smaller grants that aid firms in obtaining SBIR (Small 
Business Innovation Research) and STTR (Small Business Technology Transfer) awards.  
Finally, states are encouraging greater funding through the use and support of venture  
capital, accomplished in three ways: creating a fund that makes direct investments, investing 
in private funds which then invest in state companies, or creating a fund that invests in private 
venture capital funds. The Battelle Memorial Institute study notes that the most popular option 
is investing in private venture funds that agree to attempt to invest in state-based companies.
The creation of business incubators and technology research parks allows states to provide
bioscience companies with the necessary lab and office space. Wet-lab-equipped space,
particularly, is demanded in the bioscience sector. Forty-three states have wet-lab-equipped
incubators, while the Battelle Memorial Institute study identified a total of 114 bioscience
incubators, some with their own investment funds. Three states have dedicated bioscience
facilities funds. Along with incubators, research parks provide support to bioscience ventures 
and can also help to encourage academic/industrial partnerships. Twenty-eight bioscience 
research parks currently exist and, at the time of Battelle’s study, twenty bioscience parks 
were under development. Finally, states are designating multi-use zones around universities 
and medical complexes to encourage development.
A skilled workforce is vital to states’ attractiveness to bioscience firms. First, in order to  
address existing talent needs, states have implemented programs that bring entrepreneurs 
and successful business practitioners together for advice, insights, and guidance. Moreover, 
bioscience internship and entrepreneurial education programs have been created to assist in 
attracting individuals. Education is an important component for states’ future levels of  
competitiveness among bioscience companies. Bioscience-based degree programs and  
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curriculum additions at the college level have been a recent trend, while middle and high 
school outreach programs can give students information about bioscience career  
opportunities.
States are competing on a wide range of fronts to attract bioscience companies. From R&D
facilities to funding programs, financing options to educational enhancements, states are
implementing initiatives that they hope will position them to be an attractive environment for
bioscience companies. With such varied initiatives, it is imperative that states remain aware of
the most successful ventures implemented by other states and then adapt or improve their
approach to position themselves for bioscience investment.
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West Virginia State Initiatives Promoting the  
Bioscience Industry
In West Virginia, bioscience research facility investments are located primarily at West Virginia
University (WVU) and Marshall University, with much more limited research at the West  
Virginia School for Osteopathic Medicine (WVSOM). In addition, supporting and collaborative
programs are also located elsewhere in the state. The following section describes some of 
these programs but is not inclusive of all initiatives.13
At WVU, the Blanchette Rockefeller Neuroscience Institute is projected to open in 2008 as will
the Biomedical Science Research Laboratory Facility. An expansion is under construction at 
the Mary Babb Randolph Cancer Center, and new research space is located in the Health 
Sciences Center Library. Funding for the Blanchette Rockefeller Neuroscience Institute was 
accomplished through bond issuance, while three state development agencies composed 
a funding package for the other WVU facility investments. The WVU Biomedical Science 
Research Laboratory Facility is also projected to open in 2008, providing facilities for the 
expanded research program within the Health Sciences Center.
The Chemical Alliance Zone Biotechnology and Allied Sciences Incubation Center, in South
Charleston, provide laboratory and office space, and business services. West Virginia  
University is in the process of building a research park in Morgantown that will house a  
business incubator, supplementing a current incubator located in the WVU Research building. 
The latter incubator now houses 12 start-up firms, including three in the bioscience area.
The Velocity Center is a $7 million business incubator located at Kinetic Park in Huntington
which will work with the Robert C. Byrd Biotechnology Center at Marshall University. Finally,
the Institute for the Development of Entrepreneurial Advances, also at Marshall, will  
establish an $8.2 million, 22,000-square-foot incubator primarily geared towards  
commercializing research in molecular life sciences and medicine.
At Marshall University, the Robert C. Byrd Biotechnology Sciences Center opened in August 
of 2006 and aims to facilitate interdisciplinary research between the College of Science and 
School of Medicine. Also, the proposed MU Biotechnology Development Center will provide 
support for the commercialization of scientific concepts and for non-university affiliated biotech
companies in need of R&D resources. A recent addition to the MU Forensic Science Center
provided additional classrooms and DNA laboratories. Finally, the Edwards Comprehensive
Cancer Center opened in January of 2006, offering advanced linear accelerator technology 
and other enhanced diagnostic and treatment options.
While appropriate R&D facilities are essential to encouraging bioscience sector growth, so are
effective research programs. These can include direct grant programs specifically targeted to 
the biosciences, seed funding provided to researchers in search of federal funds, and support 
for educational institutions in their funding pursuits. Twenty-seven states have implemented 
13  The examples provided were largely based on web-based research.
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some sort of bioscience research program, many with annual funding levels to support  
research efforts. 
The West Virginia Experimental Program to Stimulate Competitive Research (EPSCoR) 
focuses on fostering research competitiveness and collaboration among institutions,  
individuals, and teams. It develops, administers, manages, and implements West Virginia’s 
experimental research improvement program. Also, the grant-funded Biometrics Knowledge 
Center at WVU conducts interdisciplinary biometrics-focused research. Finally, the Marshall 
University Forensic Science Center, with assistance from both the U.S. and West Virginia 
departments of agriculture, is creating a bacterial source tracking database which will assist in 
identifying sources of contamination and lead to remediation efforts in five major West Virginia 
watersheds.
Promising research discoveries must have access to an efficient commercialization process.
States are providing funding to universities in order to build technology transfer and
commercialization capacity, as well as supporting free-standing commercialization centers.
Moreover, commercialization funds have been created by twenty-three states for early-stage
activities. More widespread are states’ efforts geared towards assisting entrepreneurs and
emerging companies; forty-six states reported having an entrepreneurial assistance program, 
but only eight had bioscience-specific programs.
The Institute for the Development of Entrepreneurial Advances at Marshall University focuses
on commercializing technology findings, with an emphasis on biotechnology, and was funded
with the sale of $1 million in state tax credits. The institute will establish a business incubator,
collaborate with the Marshall Center for Business and Economic Research to increase  
research dollars, and connect entrepreneurs with faculty researchers. Focusing exclusively 
on West Virginia innovators, the INNOVA Commercialization Group is an initiative of the West 
Virginia High Technology Consortium Foundation whose mission is to create wealth for West 
Virginia by providing business development assistance and necessary capital.
Finally, the Mid-Atlantic Technology, Research, and Innovation Center (MATRIC), provides
product incubation services, access to facilities, and technical talent primarily for the  
disciplines of chemistry, biotechnology and the biosciences, and software systems. MATRIC 
has developed partnerships with many West Virginia educational institutions and provides 
R&D services to numerous clients. MATRIC is currently in a growth period, capitalizing on the 
intellectual resources available in the Kanawha Valley. MATRIC currently occupies about 25 
offices and 14 labs in Building 740 at the South Charleston Technology Park. Union Carbide 
Corporation, a subsidiary of Dow Chemical, donated the building to West Virginia University in 
August, 2007. The facility now serves as WVU’s Charleston Research Campus, and MATRIC 
leases space to house its Kanawha Valley operations.
Access to capital is an essential piece of building a research-intensive industry, and states 
offer a wide-range of financing options. Many states, including West Virginia, have a seed-
capital tax credit, while some also support pre-seed and seed funds. Other efforts include  
assistance in obtaining SBIR (Small Business Innovation Research) and STTR (Small  
Business Technology Transfer) awards, fund-matching programs, and bridge funding. States 
have also increased the availability of venture capital to bioscience companies by creating 
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funds that invest directly in companies, investing in privately managed funds that will invest in 
state companies, and creating funds which invest in privately managed funds that will invest 
in state companies. 
The West Virginia Jobs Investment Trust (JIT) is a public venture capital fund that invests in
early-stage, later-stage, and mature small companies looking to expand. With the goal of
developing, promoting, and expanding West Virginia’s economy, JIT has invested $4 million in
each of the following funds: Adena Ventures, Anthem Capital, Mountaineer Capital LP, PA
Early Stage, Toucan Capital, and Walker Ventures. Also, the West Virginia Economic
Development Authority provides direct and indirect financing for businesses, including an
enhanced loan insurance program for technology-based products and processes.
A skilled workforce is vital to enhancing a region’s growth prospects and states are
implementing programs that encourage the development of strong local talent. These efforts
include programs which link bioscience entrepreneurs and researchers with mentors, identify
‘coaches’ that can assist entrepreneurs in their early ventures, and encourage entrepreneurial
education through internships and fellowships. Also, states are creating outreach programs in
order to better understand bioscience companies’ needs, and then transferring this knowledge 
to colleges and secondary schools to enhance curricula. Finally, K-12 students and teachers 
are being exposed to the bioscience sector and its potential careers through specialized  
bioscience high schools, academies, institutes, and seasonal camps.
In West Virginia, the Marshall/West Virginia Science Technology Engineering Math Academy,
which supports and encourages participation in these fields, will be established by Marshall
University. At WVU, the Forensic Identification and Biometrics Degree program incorporates
academic and research activities in biometric and forensic investigative science.
The most recent development is Governor Joe Manchin’s legislative proposal for a “Bucks For
Jobs” initiative, part of which involves the creation of the West Virginia Research Trust Fund
(SB287). This major initiative builds on the West Virginia Research Challenge Fund created in
2004, which provides around $4 million each year to support creation of research centers that
foster economic development. In the FY2008 budget, $10 million was included to assist in
building the WVU and Marshall research programs. The next step entails the WVRTF, which
infuses $50 million that will support the recruitment of world-class scholars and scientists, 
along with associated research staff and infrastructure. The WVRTF will provide state funds 
to match private donations with 70 percent of the funds allocated to WVU and 30 percent 
to Marshall. The funds must be targeted to six research areas, one of which are biological, 
biotechnological and biomedical sciences.
West Virginia has numerous efforts underway as well as new initiatives that will create an
environment that is more attractive and welcoming to the bioscience sector. However, it is
important to evaluate the initiatives that have recently been completed, are ongoing, or are
planned in other states, in order to gauge West Virginia’s relative strengths and weaknesses. 
As mentioned above, state strategies can be categorized into building research and  
development capacity, encouraging academic-industry interaction, commercializing  
technology and discoveries, enhancing access to capital, providing space for bioscience 
companies, and addressing educational and skill needs. In order to remain competitive in the 
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bioscience realm, West Virginia must continue to assess the sector’s needs in order to make 
existing programs more effective and to assist in the creation and implementation of new 
programs that the sector, and its companies, will find attractive and beneficial.
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The Economic Impact of West Virginia’s  
Bioscience Industry 2006
While the bioscience industry appears to be a small but significant sector in West Virginia, a
more comprehensive view is available through the estimation of the indirect and induced
economic impacts associated with the industry. The indirect impacts result from the bioscience
firms’ purchases from their suppliers, and they, in turn, purchase from their suppliers. The
induced effects occur from the purchases by households whose members are employed 
by the bioscience industry. These economic impacts are estimated through the use of the 
IMPLAN® economic impact modeling system (www.implan.com) and the definitions of the 
impacts are included in Table 7 in the Appendix.
The economic impacts estimated include business volume, employment, output, employee
compensation, value added and assorted state taxes. Table 3 provides the estimates of the
economic impact of biosciences in West Virginia in 2005. The total economic impact was $7.2
billion in business volume, 21,935 jobs (full- and part-time), $6.1 billion in output, $1.0 billion
in employee compensation, $1.9 billion in value added and nearly $57 million in assorted state
taxes. 
An additional economic impact of the bioscience industry relates to the research undertaken 
by West Virginia University, Marshall University and the West Virginia School of Osteopathic
Medicine. While both WVU and Marshall have fairly extensive research enterprises spanning 
a wide variety of fields inclusive of biosciences, the focus of this section is on research
expenditures in the life sciences as defined by the National Science Foundation’s annual  
survey of research and development expenditures at universities and colleges.14 
14  The definition of life sciences is inclusive of agriculture, biological, medical and other related research areas. Institutions were 
requested to provide the data reported to the NSF so that comparable information would be available in the event this report was 
updated. West Virginia University and Marshall University provided data in the NSF report format. The WVSOM did not have an 
NSF report but provided data on research expenditures.
32
During FY2007, the total life sciences research and development expenditures at the three
institutions were: WVU—$85,556,000; Marshall—$13,939,000; and WVSOM—$349,000. In 
all three institutions a portion of the expenditures were directed toward equipment procure-
ment, most of which was probably supplied by firms outside of West Virginia. The latter repre-
sents a leakage from the West Virginia economy. The bulk of the expenses were for personal  
services, fringe benefits and current expenses.
The direct, indirect and induced, and total economic impacts associated with the research 
and development expenditures by the three institutions were estimated and are reported in 
Tables 4-6. An examination of these results indicates that the economic impacts associated 
with life sciences research are considerable.
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